GlassScriptPhysician profile
Karen Halasan
NPI 1508029836
$6,299.39
in general payments reported to CMS, 2019-2025
35 companies · $477 in 2025
The $477 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $560 · 2021: $756 · 2022: $1,015 · 2023: $1,117 · 2024: $2,031 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,262 · Education: $364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,262.04 |
| Education | $363.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,288.29 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $799.96 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Mallinckrodt Hospital Products INC. | $540.16 | 2021-2024 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $429.34 | 2021-2024 | Glassia, Cuvitru, Hyqvia |
| Regeneron Healthcare Solutions, INC. | $428.28 | 2019-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $424.87 | 2019-2024 | Opsumit, Uptravi |
| Genzyme Corporation | $341.67 | 2019-2025 | |
| Amgen INC. | $327.33 | 2022-2024 | Tezspire, Actimmune |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.93 | 2019-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Pfizer INC. | $204.18 | 2021-2024 | |
| Genentech USA, INC. | $180.89 | 2021-2024 | Xolair |
| Grifols USA, LLC | $143.20 | 2024-2025 | Prolastin-C Liquid |
| Insmed, INC. | $137.88 | 2021-2024 | Arikayce |
| Janssen Pharmaceuticals, INC | $116.10 | 2019-2022 | |
| Covis Pharma Gmbh | $65.96 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $58.19 | 2023-2024 | Zerbaxa, Recarbrio |
| Teva Pharmaceuticals USA, INC. | $56.22 | 2020-2021 | |
| United Therapeutics Corporation | $53.41 | 2023-2024 | Tyvaso |
| Harmony Biosciences LLC | $45.53 | 2023-2024 | Wakix |
| Inspire Medical Systems, INC. | $45.25 | 2024 | Inspire |
| Ethicon INC. | $41.92 | 2020 | |
| Viatris Specialty LLC | $39.05 | 2025 | Yupelri |
| Jazz Pharmaceuticals INC. | $31.08 | 2024 | |
| Baxter Healthcare | $30.87 | 2023 | Hillrom - Life 2000 Ventilation System |
| Alexion Pharmaceuticals, INC. | $29.95 | 2019 | |
| Inogen, INC. | $29.86 | 2024 | |
| Resmed Corp | $24.78 | 2025 | |
| Optinose US, INC. | $24.41 | 2024 | |
| Alk-Abello, INC | $24.28 | 2024 | Ragwitek, Odactra, Grastek |
| Pulmonx Corporation | $23.69 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Electromed, INC. | $22.22 | 2023 | Smartvest |
| Novartis Pharmaceuticals Corporation | $20.25 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.54 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.22 | 2019 | |
| Nabriva Therapeutics, Plc | $15.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Halasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.